376 related articles for article (PubMed ID: 15670612)
1. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.
Pertwee RG
Life Sci; 2005 Feb; 76(12):1307-24. PubMed ID: 15670612
[TBL] [Abstract][Full Text] [Related]
2. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological actions of cannabinoids.
Pertwee RG
Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
[TBL] [Abstract][Full Text] [Related]
4. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
Savinainen JR; Saario SM; Niemi R; Järvinen T; Laitinen JT
Br J Pharmacol; 2003 Dec; 140(8):1451-9. PubMed ID: 14623770
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.
Mukhopadhyay P; Bátkai S; Rajesh M; Czifra N; Harvey-White J; Haskó G; Zsengeller Z; Gerard NP; Liaudet L; Kunos G; Pacher P
J Am Coll Cardiol; 2007 Aug; 50(6):528-36. PubMed ID: 17678736
[TBL] [Abstract][Full Text] [Related]
6. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
7. Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists.
Gullapalli S; Amrutkar D; Gupta S; Kandadi MR; Kumar H; Gandhi M; Karande V; Narayanan S
Neuropharmacology; 2010 Jun; 58(8):1215-9. PubMed ID: 20214912
[TBL] [Abstract][Full Text] [Related]
8. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
9. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
Silvestri C; Di Marzo V
Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT
McLaughlin PJ; Jagielo-Miller JE; Plyler ES; Schutte KK; Vemuri VK; Makriyannis A
Psychopharmacology (Berl); 2017 Mar; 234(6):1029-1043. PubMed ID: 28144708
[TBL] [Abstract][Full Text] [Related]
11. Antidote to cannabinoid intoxication: the CB
Pryce G; Baker D
Br J Pharmacol; 2017 Nov; 174(21):3790-3794. PubMed ID: 28800377
[TBL] [Abstract][Full Text] [Related]
12. Effects of Chronic Alcohol Exposure on the Modulation of Ischemia-Induced Glutamate Release via Cannabinoid Receptors in the Dorsal Hippocampus.
Zheng L; Wu X; Dong X; Ding X; Song C
Alcohol Clin Exp Res; 2015 Oct; 39(10):1908-16. PubMed ID: 26343919
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid CB
Chen W; Liu H; Guan H; Xue N; Wang L
Eur J Pharmacol; 2017 Nov; 814():232-239. PubMed ID: 28844874
[TBL] [Abstract][Full Text] [Related]
15. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors.
MacLennan SJ; Reynen PH; Kwan J; Bonhaus DW
Br J Pharmacol; 1998 Jun; 124(4):619-22. PubMed ID: 9690851
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of Cocaine-Induced Conditioned Place Preference and Motor Activity via Cannabinoid CB2 Receptor Agonism and CB1 Receptor Antagonism in Rats.
Delis F; Polissidis A; Poulia N; Justinova Z; Nomikos GG; Goldberg SR; Antoniou K
Int J Neuropsychopharmacol; 2017 Mar; 20(3):269-278. PubMed ID: 27994006
[TBL] [Abstract][Full Text] [Related]
17. Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions.
Darmani NA
Methods Mol Med; 2006; 123():169-89. PubMed ID: 16506408
[TBL] [Abstract][Full Text] [Related]
18. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
19. Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats.
Limebeer CL; Vemuri VK; Bedard H; Lang ST; Ossenkopp KP; Makriyannis A; Parker LA
Br J Pharmacol; 2010 Sep; 161(2):336-49. PubMed ID: 20735419
[TBL] [Abstract][Full Text] [Related]
20. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
Schoffelmeer AN; Hogenboom F; Wardeh G; De Vries TJ
Neuropharmacology; 2006 Sep; 51(4):773-81. PubMed ID: 16806307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
